KEGG DRUG: Capecitabine

DRUG: Capecitabine

Entry

D01223                      Drug

Name

Capecitabine (JAN/USP/INN);
Xeloda (TN)

Product

XELODA (Genentech), XELODA (H2-Pharma)

Generic

CAPECITABINE (Accord Healthcare), CAPECITABINE (American Health Packaging), CAPECITABINE (Ascend Laboratories), CAPECITABINE (Aurobindo Pharma Limited), CAPECITABINE (BluePoint Laboratories), CAPECITABINE (CELLTRION USA), CAPECITABINE (Camber Pharmaceuticals), CAPECITABINE (Chartwell RX), CAPECITABINE (Cipla USA), CAPECITABINE (Dr. Reddy's Laboratories Limited), CAPECITABINE (Golden State Medical Supply), CAPECITABINE (Golden State Medical Supply), CAPECITABINE (Hikma Pharmaceuticals USA), CAPECITABINE (Lifestar Pharma LLC), CAPECITABINE (MSN LABORATORIES PRIVATE LIMITED), CAPECITABINE (NORTHSTAR RXLLC), CAPECITABINE (Novadoz Pharmaceuticals LLC), CAPECITABINE (Pilnova Pharma), CAPECITABINE (Quallent Pharmaceuticals Health LLC), CAPECITABINE (Sun Pharmaceutical Industries), CAPECITABINE (Teva Pharmaceuticals USA), CAPECITABINE (Teyro Labs Private Limited), CAPECITABINE 150MG (Armas Pharmaceuticals), CAPECITABINE 500MG (Armas Pharmaceuticals)

Formula

C15H22FN3O6

Exact mass

359.1493

Mol weight

359.3501

Structure

Simcomp

Class

Antineoplastic
DG02018  Antimetabolite
  DG01958  Nucleic acid derivative, antineoplastic
   DG01935  Fluoropyrimidine antineoplastic
Metabolizing enzyme substrate
DG01642  CYP2C9 substrate

Remark

Same as:

C12650

Therapeutic category:

4223

ATC code:

L01BC06

Product:

D01223<JP/US>

Efficacy

Antineoplastic, Antimetabolite

Disease

Colorectal cancer [DS:H00020]
Breast cancer [DS:H00031]
Gastric cancer [DS:H00018]
Esophageal cancer [DS:H00017]
Pancreatic cancer [DS:H00019]

Comment

Active form of prodrug: Fluorouracil [DR:D00584]

Target

TYMS [HSA:7298] [KO:K00560]

Pathway

hsa00240

Pyrimidine metabolism

hsa00670

One carbon pool by folate

Metabolism

Enzyme: CYP2C9 [HSA:1559]

Interaction

Structure map

map07041

Antineoplastics - antimetabolic agents

Other map

map00983

Drug metabolism - other enzymes

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01B ANTIMETABOLITES
    L01BC Pyrimidine analogues
     L01BC06 Capecitabine
      D01223  Capecitabine (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Antimetabolites
   Capecitabine
    D01223  Capecitabine (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   422  Antimetabolites
    4223  Fluorouracils
     D01223  Capecitabine (JAN/USP/INN)
Drug groups [BR:br08330]
Antineoplastic
  DG02018  Antimetabolite
   DG01958  Nucleic acid derivative, antineoplastic
    DG01935  Fluoropyrimidine antineoplastic
     D01223  Capecitabine
Metabolizing enzyme substrate
  DG01642  CYP2C9 substrate
   D01223  Capecitabine
Drug classes [BR:br08332]
Antineoplastic
  DG02018  Antimetabolite
   D01223  Capecitabine
Target-based classification of drugs [BR:br08310]
Enzymes
  Transferases (EC2)
   Methyltransferases
    TYMS
     D01223  Capecitabine (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D01223
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D01223
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D01223
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
  D01223

Other DBs

CAS:	154361-50-9

PubChem:

ChEBI:

LigandBox:

NIKKAJI:

KCF data

ATOM        25
            1   C1y C    11.2700  -21.5600
            2   C1y C    12.6700  -21.5600
            3   C1y C    13.1600  -20.2300
            4   O2x O    11.9700  -19.4600
            5   C1y C    10.8500  -20.2300
            6   C1a C     9.5200  -19.8100
            7   O1a O    10.4300  -22.7500
            8   O1a O    13.5100  -22.7500
            9   N4y N    14.4900  -19.8100
            10  C8y C    15.6800  -20.5100
            11  N5x N    16.9400  -19.8100
            12  C8y C    16.9400  -18.4100
            13  C8y C    15.7500  -17.7100
            14  C8x C    14.4900  -18.4100
            15  O5x O    15.6800  -21.9100
            16  X   F    15.7500  -16.3800
            17  N1b N    18.1300  -17.7100
            18  C7a C    19.3200  -18.4100
            19  O7a O    20.5100  -17.7100
            20  C1b C    21.7000  -18.4100
            21  C1b C    22.8900  -17.7100
            22  C1b C    24.0800  -18.4100
            23  C1b C    25.2700  -17.7100
            24  C1a C    26.4600  -18.4100
            25  O6a O    19.3200  -19.8100
BOND        26
            1     1   2 1
            2     2   3 1
            3     3   4 1
            4     4   5 1
            5     1   5 1
            6     5   6 1 #Up
            7     1   7 1 #Down
            8     2   8 1 #Down
            9     3   9 1 #Up
            10    9  10 1
            11   10  11 1
            12   11  12 2
            13   12  13 1
            14   13  14 2
            15    9  14 1
            16   10  15 2
            17   13  16 1
            18   17  18 1
            19   17  12 1
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   18  25 2

» Japanese version » Back

DBGET integrated database retrieval system